These observations correspond with previous comparisons made by other scientists claiming that the majority of mutations of TP53 in pancreatic cancer (approx. 2/3) are missense mutations, followed by truncating mutations (approx. 1/3) [42]. This evidence concerns the gene TP53 and pancreatic neoplasm.